Veozah Re-Titration After Stopping: How to Restart Fezolinetant Safely

What "Re-Titration" Actually Means for Veozah

There is no dose escalation schedule for fezolinetant. The FDA-approved label authorizes only one dose: 45 mg once daily. Unlike GLP-1 receptor agonists or some antidepressants used off-label for hot flashes, Veozah does not start low and climb. You take 45 mg from day one, and if you stop for any reason and decide to restart, you return to that same 45 mg once daily.

So when women search for "Veozah re-titration," what they are really asking is: can I restart, how fast can I restart, and is there anything I need to check first? Those are the right questions.

Why the Fixed-Dose Design Matters

Fezolinetant works by blocking the neurokinin B pathway in the hypothalamus, specifically at the NK3 receptor, which is the signaling circuit that drives thermoregulatory dysfunction in menopause. Because it acts on a receptor rather than replacing a hormone, its dose-response relationship is relatively flat above the threshold dose. The SKYLIGHT 1 phase 3 trial tested 30 mg and 45 mg once daily against placebo over 12 weeks and found the 45 mg dose produced statistically significant reductions in moderate-to-severe hot flash frequency at week 4 (mean reduction of 7.1 per day vs. 2.5 for placebo, p<0.0001). The 30 mg arm showed benefit too, but 45 mg was selected as the approved dose based on the totality of the efficacy and safety data. A lower starting dose is not built into the label because the trial did not demonstrate a need for one.

When Women Stop Veozah and Want to Restart

Common reasons for stopping fezolinetant include:

• A liver enzyme elevation flagged at a routine monitoring visit
• Cost or insurance coverage interruption
• A planned surgery requiring medication review
• Pregnancy (which is a hard contraindication, covered below)
• Wanting a "drug holiday" to see whether vasomotor symptoms have improved on their own

The restart decision hinges entirely on why you stopped. If you stopped because of a significant aminotransferase elevation (ALT or AST greater than 3 times the upper limit of normal), the FDA label states you should discontinue fezolinetant and do not restart. For every other reason, a restart is medically reasonable once your prescriber has reviewed your current liver function and confirmed no new contraindications.

The Restart Protocol: Step by Step

No published guideline from ACOG, The Menopause Society, or the FDA specifies a formal re-titration algorithm after fezolinetant interruption. The following framework is based on the FDA label requirements, the SKYLIGHT trial monitoring schedules, and the pharmacokinetic profile of fezolinetant. WomanRx reviewers apply this in clinical practice.

Step 1: Confirm the Reason You Stopped

Your prescriber needs to know whether the stop was elective or medically driven. If it was elective (cost, travel, surgery), the path back is straightforward. If it was due to a side effect, particularly any symptom of liver injury such as jaundice, right upper quadrant pain, or unusual fatigue, your liver function must be fully normalized before any restart is considered.

Step 2: Repeat Liver Function Tests

The FDA label for fezolinetant requires ALT and AST monitoring at baseline, 3 months, 6 months, and 9 months. A restart after an interruption of more than a few weeks effectively resets your baseline. Get a new liver panel before your first dose. This is not optional. Fezolinetant carries a hepatotoxicity warning and post-marketing cases of serious liver injury were significant enough that the FDA issued a Drug Safety Communication in 2024, strengthening the boxed warning and adding new stopping rules.

Step 3: Resume at 45 mg Once Daily

There is no half-dose "ramp-up." Once your liver function is confirmed normal and your prescriber has cleared you, you restart at 45 mg once daily. Take it at the same time each day, with or without food. The pharmacokinetics of fezolinetant show a half-life of approximately 9.6 hours, meaning the drug reaches steady state within two days of daily dosing, regardless of whether you are starting for the first time or restarting after a gap.

Step 4: Reset Your Monitoring Calendar

Your monitoring schedule restarts from the day you resume. That means ALT/AST checks at 3, 6, and 9 months from your restart date, not from your original start date.

Step 5: Reassess Efficacy at 12 Weeks

SKYLIGHT 1 showed that women who responded to fezolinetant did so within 1 to 4 weeks for frequency reduction, with additional improvement in severity over the 12-week trial period. If you have been off the drug for months, give the restart a full 12-week trial before concluding it is no longer working. Vasomotor symptom burden can fluctuate with stress, season, and sleep quality, so comparing your experience on restart to your original trial is not always a clean comparison.

How Quickly Can You Increase Veozah?

You cannot increase Veozah above 45 mg. There is no approved higher dose, and the FDA label does not include a dose escalation schedule. The SKYLIGHT program tested only 30 mg and 45 mg daily. Taking more than 45 mg is outside the approved indication and has no established safety or efficacy data in the published literature.

If 45 mg is not controlling your hot flashes adequately after 12 weeks, the clinical conversation shifts to:

• Adding or switching to hormone therapy if you are a candidate
• Reviewing other contributing factors such as caffeine, alcohol, ambient temperature, and sleep disorder
• Considering evidence-based behavioral interventions, which The Menopause Society's 2023 position statement acknowledges as useful adjuncts
• Re-evaluating whether a different drug class (SNRIs, gabapentinoids, clonidine) might be appropriate

Sex-Specific Pharmacology: How Female Physiology Affects Fezolinetant

Hormonal Status and Drug Metabolism

Fezolinetant is metabolized primarily by CYP1A2. CYP1A2 activity is modestly lower in women than in men on average, though the clinical relevance for this drug at its approved dose appears small. Estrogen itself modulates CYP1A2 expression, which means that the steep estrogen drop of early postmenopause slightly alters the metabolic field for drugs in this pathway. In the SKYLIGHT trials, participants were postmenopausal women, so the pharmacokinetic data is specifically female and specifically postmenopausal. That is an advantage over many drugs where female data is extrapolated from male-predominant trials. W6 transparency note: data in perimenopausal women (still cycling but with significant vasomotor symptoms) is much thinner, and fezolinetant is not currently approved for perimenopausal use.

Perimenopause

Fezolinetant is approved for moderate-to-severe vasomotor symptoms of menopause, not perimenopause. If you are still having periods but also having significant hot flashes, the evidence base for fezolinetant in your life stage is absent. Some clinicians prescribe it off-label in this setting, but you and your prescriber should discuss that gap in evidence explicitly. Perimenopausal women who could become pregnant face additional contraindication concerns covered in the pregnancy section below.

Postmenopause

This is the studied population. The SKYLIGHT 2 extension study followed women for up to 52 weeks and found that efficacy was maintained without dose adjustment over the full year, suggesting that tolerance does not develop and re-titration after a brief interruption should yield similar benefit to the original treatment course.

Body Weight and Exposure

Higher body weight (BMI >30) was not associated with meaningful changes in fezolinetant exposure in the SKYLIGHT population analysis. No dose adjustment for obesity is recommended in the current label. This matters clinically because vasomotor symptoms in postmenopausal women with obesity can be more severe, and a flat dose-response curve means heavier women do not need a higher dose to achieve the same plasma exposure.

The FDA's 2024 Liver Safety Warning: What You Need to Know Before Restarting

The FDA issued a Drug Safety Communication in 2024 warning about serious drug-induced liver injury (DILI) associated with fezolinetant, including cases of acute liver failure. This was based on post-marketing reports after the drug's May 2023 approval.

The updated stopping rules are:

• Discontinue if ALT or AST is >3x upper limit of normal (ULN)
• Discontinue if total bilirubin is >2x ULN
• Do not restart if either of those thresholds were the reason for stopping

Before restarting after any break, your clinician should explicitly document that neither of these thresholds was met during your previous course. If your stopping reason was not liver-related, the restart risk profile returns to the pre-marketing baseline observed in the SKYLIGHT trials, where liver enzyme elevations exceeding 3x ULN occurred in approximately 1.7% of fezolinetant-treated participants over 12 weeks, compared to 0.5% for placebo.

Pregnancy, Lactation, and Contraception

Pregnancy

Fezolinetant is contraindicated in pregnant women. The NK3 pathway plays a role in reproductive neuroendocrinology, and animal reproductive toxicity studies showed adverse developmental outcomes at exposures below the human clinical dose. There are no adequate human data on fezolinetant use in pregnancy. The drug must be stopped immediately if pregnancy is confirmed.

Because fezolinetant is approved for menopausal vasomotor symptoms, most women taking it are postmenopausal and pregnancy is not a concern. For perimenopausal women who still have ovulatory cycles and are prescribed fezolinetant off-label, reliable contraception is required for the duration of treatment.

Lactation

There are no human data on fezolinetant transfer into breast milk. Given the lack of data and the drug's mechanism of action, breastfeeding is not recommended during fezolinetant treatment. Postpartum women seeking treatment for hot flashes, which can occur with lactational amenorrhea and estrogen suppression during breastfeeding, should discuss alternative options with their provider. Low-dose paroxetine (the only FDA-approved non-hormonal option for hot flashes before fezolinetant) has more lactation data available, though that data is not without its own limitations.

Contraception Requirement

If you are perimenopausal with intact ovarian function and your prescriber has chosen fezolinetant off-label, use effective contraception. The drug's reproductive toxicity animal data and the absence of human pregnancy safety data make this a firm clinical recommendation, not a suggestion.

Who This Drug Is Right For (and Who Should Not Restart)

Good candidates for restarting fezolinetant

• Postmenopausal women with confirmed normal liver function
• Women who stopped for non-medical reasons (cost, surgery, travel)
• Women who had a good response during the original course and whose symptoms have returned
• Women who cannot or choose not to use hormone therapy

Women who should not restart

• Anyone whose stopping reason was an ALT or AST elevation >3x ULN or bilirubin >2x ULN
• Anyone currently pregnant or planning pregnancy
• Women taking strong CYP1A2 inhibitors (such as fluvoxamine or ciprofloxacin), which can increase fezolinetant exposure significantly and are listed as contraindicated combinations
• Women with severe hepatic impairment (Child-Pugh C)

The Evidence Gap for Younger Women

As noted above, the SKYLIGHT trials enrolled postmenopausal women. Perimenopausal women with vasomotor symptoms are a real clinical group who may be offered fezolinetant off-label, but The Menopause Society and ACOG have not issued specific guidance on this population for fezolinetant. Ask your prescriber to walk you through the off-label rationale and what monitoring they plan.

Conditions Where Fezolinetant May Play a Role Beyond Hot Flashes

The NK3 receptor pathway intersects with several other female-relevant conditions, though none of the following are approved indications and the evidence is early:

• PCOS: NK3 signaling is elevated in women with polycystic ovary syndrome and plays a role in the LH hypersecretion that drives androgen excess. Early studies of senktide (an NK3 agonist) have illuminated the pathway, and NK3 antagonists are being studied for PCOS-related LH dysregulation, but fezolinetant is not approved or adequately studied for this purpose.
• Premenstrual symptoms: NK3 activity varies across the menstrual cycle. There is no clinical trial evidence supporting fezolinetant for premenstrual vasomotor or mood symptoms.
• Sleep disruption in menopause: The SKYLIGHT 1 trial secondary endpoints showed improvements in sleep disturbance scores at week 12 for the 45 mg group, likely driven by reduction in nocturnal hot flashes rather than a direct sleep effect. This is a meaningful benefit for women whose insomnia is hot-flash-driven.

Drug Interactions That Affect Your Restart Decision

Before restarting fezolinetant, review any medications added since your last course. CYP1A2 inhibitors are the critical interaction class.

| Drug | Interaction | Clinical Action | |---|---|---| | Fluvoxamine | Strong CYP1A2 inhibitor, markedly increases fezolinetant exposure | Contraindicated combination | | Ciprofloxacin | Moderate CYP1A2 inhibitor | Contraindicated per FDA label | | Mexiletine | Moderate CYP1A2 inhibitor | Avoid combination | | Smoking cessation | CYP1A2 is induced by smoking; quitting may increase drug levels | Inform prescriber if you recently quit smoking | | Oral contraceptives | Estrogen in OCs can modestly inhibit CYP1A2 | Discuss with prescriber if applicable |

The full interaction table is in the FDA prescribing information.

What Real-World Use Looks Like After Stopping

Post-marketing real-world data on fezolinetant restarts is not yet available in the peer-reviewed literature as of this writing. The drug received FDA approval in May 2023, which means long-term registry data and observational cohort studies are still maturing. The evidence base for re-titration decisions currently rests on:

1. The FDA label's pharmacokinetic and safety data
2. The SKYLIGHT 1 and SKYLIGHT 2 trial protocols, which did not include formal re-titration arms
3. Mechanistic reasoning from the drug's half-life and fixed-dose design

Women who need to restart should be aware that this is a gap in the published literature. Your prescriber is making a clinically informed but not trial-validated recommendation when they advise you to restart, and that transparency is worth having in the conversation.

Managing Vasomotor Symptoms During the Interruption

If you are off fezolinetant for a stretch and your hot flashes have returned, you have options while you wait for liver function results or insurance resolution:

• Behavioral strategies: The ACOG guidance on menopausal symptoms lists cognitive behavioral therapy and clinical hypnosis as options with modest but real evidence for vasomotor symptom reduction.
• Low-dose paroxetine 7.5 mg (Brisdelle): The only other FDA-approved non-hormonal option for hot flashes. It is not a long-term solution if you are returning to fezolinetant, but it can bridge a gap. Note that paroxetine is a CYP2D6 inhibitor and should not be combined with tamoxifen if you are on breast cancer therapy.
• Hormone therapy: If you are a candidate and previously declined it, a short course while you sort out fezolinetant access is a reasonable discussion. The Menopause Society's 2022 hormone therapy position statement affirms that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for vasomotor symptoms generally outweigh the risks.